Synthesis and biological evaluation of Schizandrin derivatives as potential anti-cancer agents. 2018

Devi Amujuri, and Bandi Siva, and B Poornima, and Katukuri Sirisha, and A V S Sarma, and V Lakshma Nayak, and Ashok K Tiwari, and U Purushotham, and K Suresh Babu
Division of Natural Products Chemistry, CSIR-Indian Institute of Chemical Technology, Hyderabad, 500 007, India.

A new series of Schizandrin (1) derivatives were synthesized utilizing the C-9 position of the Schizandrin core and evaluated for their cytotoxic activities against HeLa (cervical cancer), A549 (lung cancer), MCF-7 (breast cancer) and DU-145 (prostate cancer) cell lines. Among the synthesized series, 4e, 4f, 4g and 5 showed potent activities against tested cell lines. More significantly, compound 5 exhibited most potent cytotoxic activity against DU-145 with an IC50 value of 1.38 μM which is comparable to the standard agent, doxorubicin. Further, flow cytometry analysis indicated that 5 arrested cells in G2/M phase and consequently leading to apoptosis. Molecular docking analysis showed that 5 occupied the colchicine binding pocket of tubulin. Overall, the present study demonstrates that 5, as a mitotic-agent.

UI MeSH Term Description Entries
D011083 Polycyclic Compounds Compounds which contain two or more rings in their structure. Compounds, Polycyclic
D004354 Drug Screening Assays, Antitumor Methods of investigating the effectiveness of anticancer cytotoxic drugs and biologic inhibitors. These include in vitro cell-kill models and cytostatic dye exclusion tests as well as in vivo measurement of tumor growth parameters in laboratory animals. Anticancer Drug Sensitivity Tests,Antitumor Drug Screens,Cancer Drug Tests,Drug Screening Tests, Tumor-Specific,Dye Exclusion Assays, Antitumor,Anti-Cancer Drug Screens,Antitumor Drug Screening Assays,Tumor-Specific Drug Screening Tests,Anti Cancer Drug Screens,Anti-Cancer Drug Screen,Antitumor Drug Screen,Cancer Drug Test,Drug Screen, Anti-Cancer,Drug Screen, Antitumor,Drug Screening Tests, Tumor Specific,Drug Screens, Anti-Cancer,Drug Screens, Antitumor,Drug Test, Cancer,Drug Tests, Cancer,Screen, Anti-Cancer Drug,Screen, Antitumor Drug,Screens, Anti-Cancer Drug,Screens, Antitumor Drug,Test, Cancer Drug,Tests, Cancer Drug,Tumor Specific Drug Screening Tests
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000970 Antineoplastic Agents Substances that inhibit or prevent the proliferation of NEOPLASMS. Anticancer Agent,Antineoplastic,Antineoplastic Agent,Antineoplastic Drug,Antitumor Agent,Antitumor Drug,Cancer Chemotherapy Agent,Cancer Chemotherapy Drug,Anticancer Agents,Antineoplastic Drugs,Antineoplastics,Antitumor Agents,Antitumor Drugs,Cancer Chemotherapy Agents,Cancer Chemotherapy Drugs,Chemotherapeutic Anticancer Agents,Chemotherapeutic Anticancer Drug,Agent, Anticancer,Agent, Antineoplastic,Agent, Antitumor,Agent, Cancer Chemotherapy,Agents, Anticancer,Agents, Antineoplastic,Agents, Antitumor,Agents, Cancer Chemotherapy,Agents, Chemotherapeutic Anticancer,Chemotherapy Agent, Cancer,Chemotherapy Agents, Cancer,Chemotherapy Drug, Cancer,Chemotherapy Drugs, Cancer,Drug, Antineoplastic,Drug, Antitumor,Drug, Cancer Chemotherapy,Drug, Chemotherapeutic Anticancer,Drugs, Antineoplastic,Drugs, Antitumor,Drugs, Cancer Chemotherapy
D001665 Binding Sites The parts of a macromolecule that directly participate in its specific combination with another molecule. Combining Site,Binding Site,Combining Sites,Site, Binding,Site, Combining,Sites, Binding,Sites, Combining
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships
D016195 G2 Phase The period of the CELL CYCLE following DNA synthesis (S PHASE) and preceding M PHASE (cell division phase). The CHROMOSOMES are tetraploid in this point. Gap Phase 2,Second Gap Phase,G2 Phases,Gap Phase, Second,Gap Phases, Second,Phase 2, Gap,Phase, G2,Phase, Second Gap,Phases, G2,Phases, Second Gap,Second Gap Phases
D017209 Apoptosis A regulated cell death mechanism characterized by distinctive morphologic changes in the nucleus and cytoplasm, including the endonucleolytic cleavage of genomic DNA, at regularly spaced, internucleosomal sites, i.e., DNA FRAGMENTATION. It is genetically programmed and serves as a balance to mitosis in regulating the size of animal tissues and in mediating pathologic processes associated with tumor growth. Apoptosis, Extrinsic Pathway,Apoptosis, Intrinsic Pathway,Caspase-Dependent Apoptosis,Classic Apoptosis,Classical Apoptosis,Programmed Cell Death,Programmed Cell Death, Type I,Apoptoses, Extrinsic Pathway,Apoptoses, Intrinsic Pathway,Apoptosis, Caspase-Dependent,Apoptosis, Classic,Apoptosis, Classical,Caspase Dependent Apoptosis,Cell Death, Programmed,Classic Apoptoses,Extrinsic Pathway Apoptoses,Extrinsic Pathway Apoptosis,Intrinsic Pathway Apoptoses,Intrinsic Pathway Apoptosis
D017705 Lignans A class of dibenzylbutane derivatives which occurs in higher plants and in fluids (bile, serum, urine, etc.) in man and other animals. These compounds, which have a potential anti-cancer role, can be synthesized in vitro by human fecal flora. (From Singleton & Sainsbury, Dictionary of Microbiology and Molecular Biology, 2d ed) Lignan,Neolignan,Neolignans
D045744 Cell Line, Tumor A cell line derived from cultured tumor cells. Tumor Cell Line,Cell Lines, Tumor,Line, Tumor Cell,Lines, Tumor Cell,Tumor Cell Lines

Related Publications

Devi Amujuri, and Bandi Siva, and B Poornima, and Katukuri Sirisha, and A V S Sarma, and V Lakshma Nayak, and Ashok K Tiwari, and U Purushotham, and K Suresh Babu
January 2019, Bioorganic & medicinal chemistry,
Devi Amujuri, and Bandi Siva, and B Poornima, and Katukuri Sirisha, and A V S Sarma, and V Lakshma Nayak, and Ashok K Tiwari, and U Purushotham, and K Suresh Babu
February 2012, Bioorganic & medicinal chemistry letters,
Devi Amujuri, and Bandi Siva, and B Poornima, and Katukuri Sirisha, and A V S Sarma, and V Lakshma Nayak, and Ashok K Tiwari, and U Purushotham, and K Suresh Babu
August 2012, Journal of enzyme inhibition and medicinal chemistry,
Devi Amujuri, and Bandi Siva, and B Poornima, and Katukuri Sirisha, and A V S Sarma, and V Lakshma Nayak, and Ashok K Tiwari, and U Purushotham, and K Suresh Babu
October 2022, International journal of molecular sciences,
Devi Amujuri, and Bandi Siva, and B Poornima, and Katukuri Sirisha, and A V S Sarma, and V Lakshma Nayak, and Ashok K Tiwari, and U Purushotham, and K Suresh Babu
August 2013, European journal of medicinal chemistry,
Devi Amujuri, and Bandi Siva, and B Poornima, and Katukuri Sirisha, and A V S Sarma, and V Lakshma Nayak, and Ashok K Tiwari, and U Purushotham, and K Suresh Babu
December 2016, Archiv der Pharmazie,
Devi Amujuri, and Bandi Siva, and B Poornima, and Katukuri Sirisha, and A V S Sarma, and V Lakshma Nayak, and Ashok K Tiwari, and U Purushotham, and K Suresh Babu
October 2018, International journal of molecular sciences,
Devi Amujuri, and Bandi Siva, and B Poornima, and Katukuri Sirisha, and A V S Sarma, and V Lakshma Nayak, and Ashok K Tiwari, and U Purushotham, and K Suresh Babu
August 2023, Bioorganic & medicinal chemistry,
Devi Amujuri, and Bandi Siva, and B Poornima, and Katukuri Sirisha, and A V S Sarma, and V Lakshma Nayak, and Ashok K Tiwari, and U Purushotham, and K Suresh Babu
January 2023, Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents,
Devi Amujuri, and Bandi Siva, and B Poornima, and Katukuri Sirisha, and A V S Sarma, and V Lakshma Nayak, and Ashok K Tiwari, and U Purushotham, and K Suresh Babu
February 2018, European journal of medicinal chemistry,
Copied contents to your clipboard!